SONOMA PHARMACEUTICALS INC (SNOA)
US83558L2043 - Common Stock
Taking everything into account, SNOA scores 2 out of 10 in our fundamental rating. SNOA was compared to 194 industry peers in the Pharmaceuticals industry. While SNOA seems to be doing ok healthwise, there are quite some concerns on its profitability. SNOA is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year SNOA has reported negative net income.
In the past year SNOA has reported a negative cash flow from operations.
In the past 5 years SNOA always reported negative net income.
SNOA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
SNOA has a Return On Assets of -33.32%. This is comparable to the rest of the industry: SNOA outperforms 53.65% of its industry peers.
The Return On Equity of SNOA (-91.58%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -33.32% | ||
| ROE | -91.58% | ||
| ROIC | N/A |
ROA(3y)-30.51%
ROA(5y)-28.12%
ROE(3y)-67.28%
ROE(5y)-66.88%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a Gross Margin value of 38.41%, SNOA perfoms like the industry average, outperforming 58.85% of the companies in the same industry.
SNOA's Gross Margin has declined in the last couple of years.
SNOA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 38.41% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.79%
GM growth 5Y-4.46%
2. Health
2.1 Basic Checks
SNOA does not have a ROIC to compare to the WACC, probably because it is not profitable.
SNOA has less shares outstanding than it did 1 year ago.
SNOA has less shares outstanding than it did 5 years ago.
The debt/assets ratio for SNOA has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -19.22, we must say that SNOA is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -19.22, SNOA is not doing good in the industry: 86.46% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.04 indicates that SNOA is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.04, SNOA is in line with its industry, outperforming 52.60% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -19.22 |
ROIC/WACCN/A
WACC8.68%
2.3 Liquidity
A Current Ratio of 3.18 indicates that SNOA has no problem at all paying its short term obligations.
SNOA has a Current ratio (3.18) which is in line with its industry peers.
SNOA has a Quick Ratio of 2.47. This indicates that SNOA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.47, SNOA is in line with its industry, outperforming 48.44% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.18 | ||
| Quick Ratio | 2.47 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 11.66% over the past year.
SNOA shows a small growth in Revenue. In the last year, the Revenue has grown by 3.90%.
Measured over the past years, SNOA shows a quite strong growth in Revenue. The Revenue has been growing by 14.73% on average per year.
EPS 1Y (TTM)11.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.83%
Revenue 1Y (TTM)3.9%
Revenue growth 3Y3.8%
Revenue growth 5Y14.73%
Sales Q2Q%31.05%
3.2 Future
Based on estimates for the next years, SNOA will show a decrease in Earnings Per Share. The EPS will decrease by -4.45% on average per year.
The Revenue is expected to grow by 3.09% on average over the next years.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3Y11.48%
EPS Next 5Y-4.45%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3Y-7.09%
Revenue Next 5Y3.09%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
SNOA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3Y11.48%
5. Dividend
5.1 Amount
SNOA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SONOMA PHARMACEUTICALS INC
NASDAQ:SNOA (11/21/2024, 8:00:02 PM)
After market: 2.84 -0.07 (-2.41%)2.91
+0.07 (+2.46%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap3.90M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -33.32% | ||
| ROE | -91.58% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 38.41% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.93
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.18 | ||
| Quick Ratio | 2.47 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)11.66%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next YN/A
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)3.9%
Revenue growth 3Y3.8%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y